Vivos Therapeutics, Inc. (VVOS)
NASDAQ: VVOS · Real-Time Price · USD
0.5720
-0.0417 (-6.79%)
Jun 12, 2026, 4:00 PM EDT - Market closed
Vivos Therapeutics Revenue
Vivos Therapeutics had revenue of $5.14M in the quarter ending March 31, 2026, with 70.46% growth. This brings the company's revenue in the last twelve months to $19.57M, up 33.77% year-over-year. In the year 2025, Vivos Therapeutics had annual revenue of $17.44M with 16.05% growth.
Revenue (ttm)
$19.57M
Revenue Growth
+33.77%
P/S Ratio
0.41
Revenue / Employee
$72,474
Employees
270
Market Cap
7.95M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 17.44M | 2.41M | 16.05% |
| Dec 31, 2024 | 15.03M | 1.23M | 8.91% |
| Dec 31, 2023 | 13.80M | -2.22M | -13.87% |
| Dec 31, 2022 | 16.02M | -861.00K | -5.10% |
| Dec 31, 2021 | 16.89M | 3.82M | 29.23% |
| Dec 31, 2020 | 13.07M | 1.67M | 14.68% |
| Dec 31, 2019 | 11.39M | 7.60M | 200.44% |
| Dec 31, 2018 | 3.79M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Tenon Medical | 4.60M |
| Biomerica | 4.33M |
| Intelligent Bio Solutions | 3.91M |
| IceCure Medical | 3.57M |
| VolitionRx | 2.47M |
| ENvue Medical | 2.18M |
| Sintx Technologies | 1.03M |
| Nexalin Technology | 275.58K |
VVOS News
- 3 days ago - Vivos Therapeutics intends to file registration statement for rights offering - TheFly
- 3 days ago - Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering - GlobeNewsWire
- 4 days ago - Vivos Therapeutics enters pact with South Palm Cardiovascular Associates - TheFly
- 4 days ago - Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients - GlobeNewsWire
- 5 days ago - Vivos Therapeutics Transcript: WTR Insights Conference: Powered by The Small Cap Showcase - Transcripts
- 5 days ago - Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026 - GlobeNewsWire
- 9 days ago - Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing - GlobeNewsWire
- 24 days ago - Vivos Therapeutics reports Q1 EPS (52c), consensus (45c) - TheFly